Monday, April 3, 2017, Washington, DC — 7:00 PM – 9:00 PM (Eastern Time)

Molecular Tumor Board: Integrating Biomarker Analyses into Clinical Decision-Making Regarding the Use of Immune Checkpoint Inhibitors in Cancer Treatment

Location:
Grand Hyatt Washington
1000 H St NW
Washington, DC 20001
Hotel Phone: (202) 582-1234

Time:
6:30 PM – 7:00 PM (Eastern Time) — Registration and Buffet Dinner
7:00 PM – 9:00 PM (Eastern Time) — Educational Program

Meeting Room:
Independence Ballroom A (Level 5B)

There is no registration fee for this event. However, preregistration is advised, as seating is limited.  
 
Faculty:
Johanna C Bendell, MD
Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute
Nashville, Tennessee

Charles G Drake, MD, PhD
Professor of Medicine
Co-Director, Cancer Immunotherapy Programs
Columbia University Medical Center
New York, New York

Roy S Herbst, MD, PhD
Ensign Professor of Medicine (Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
Smilow Cancer Hospital
New Haven, Connecticut

David F McDermott, MD
Associate Professor of Medicine
Harvard Medical School
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber Cancer Center
Boston, Massachusetts

Craig Moskowitz, MD
Clinical Director
Division of Hematologic Oncology
Attending Physician
Lymphoma and Adult BMT Services
Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College of Cornell University
New York, New York

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

This symposium is accredited by Research To Practice and supported by grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company and Incyte Corporation. This is not an official program of the Annual Meeting of the American Association for Cancer Research.

MODULE 1: Overview of Immune Checkpoint Inhibitors — Renal Cell Carcinoma and Urothelial Bladder Cancer (UBC) — Dr Drake

Faculty Presentation Topics

  • Biologic basis for immuno-oncology and processes underlying cancer immunoediting (eg, elimination, equilibrium, escape)
  • Identification of immunotherapy targets and development of rational treatment approaches
  • Challenges in biomarker development for immunotherapies; dynamic and inducible nature of immunotherapy targets; coregulators and suppressors of immune response
  • Biologic rationale for and mechanism of action of anti-PD-1/PD-L1 antibodies

Faculty Case Presentation and Discussion

Relevant Clinical Issues

  • Use of anti-PD-1/PD-L1 antibodies as first-line therapy for patients with UBC versus treatment with platinum-based chemotherapy outside of a clinical trial
  • Optimal duration of immune therapy
  • Potential contraindications to the use of checkpoint inhibitors (eg, autoimmune disease, organ transplant)
  • Utility of PD-L1 testing in clinical decision-making

MODULE 2: PD-L1 as a Predictive Biomarker in Non-Small Cell Lung Cancer (NSCLC) and Beyond — Dr Herbst

Faculty Presentation Topics

  • Current clinical trial data documenting the correlation between PD-L1 tumor proportion score and clinical response to anti-PD-1/PD-L1 antibodies
  • Factors affecting the reliability of PD-L1 immunohistochemistry as a biomarker for anti-PD-1 or anti-PD-L1 therapies
    • – Regulation of PD-L1 expression by MAPK, PI3K and other pathways; transcriptional factors (eg, HIF1, STAT3)
    • – Expression of PD-L1 on immune cells in addition to the tumor microenvironment
    • – Transient expression and intratumoral heterogeneity of PD-L1 expression
    • – Immunohistochemistry antibodies used and varying definitions of PD-L1 positivity
  • Coinhibitor and costimulatory molecules that may moderate anti-PD-1 or anti-PD-L1 therapy (eg, presence of other concurrent suppressive immune pathways, such as IDO, CTLA-4, TIM-3, OX40 and LAG3)

Faculty Case Presentation and Discussion

Relevant Clinical Issues

  • Integration of anti-PD-1/PD-L1 checkpoint inhibitors into the treatment of metastatic NSCLC and sequencing with chemotherapy and/or targeted agents
  • Effect, if any, of histology in employing anti-PD-1/PD-L1 antibody treatment
  • Immune-mediated toxicities with the use of anti-PD-1/PD-L1 antibodies and their time course and management
  • Theoretical and/or clinical differences in anti-PD-1 versus anti-PD-L1 checkpoint inhibitors

MODULE 3: Checkpoint Inhibitors in Melanoma; Tumor-Infiltrating Lymphocytes (TILs) as Predictors of Response; Investigating the Immune State of the Tumor Microenvironment — Dr McDermott

Faculty Presentation Topics

  • TILs and survival outcomes in cancer
  • CD8+ TIL density in pretreatment and post-treatment biopsies and host immune response
  • The “T-cell-inflamed” tumor phenotype and clinical benefit from immunotherapies (eg, MAGE-A3 vaccine, high-dose interleukin-2)
  • Investigations of T-cell receptor clonality and tumor-specific immune response
  • Multiplex immunohistochemistry techniques to interrogate the relationship between both tumor and immune cell phenotypes as a predictor of response

Faculty Case Presentation and Discussion

Relevant Clinical Issues

  • Integration of anti-PD-1/PD-L1 checkpoint inhibitors into the treatment of metastatic melanoma and sequencing with other available agents
  • Use of single-agent anti-PD-1 therapy versus the combination of ipilimumab and nivolumab
  • Effect, if any, of patient-specific characteristics (eg, age, obesity, LDH levels, location of tumor) on outcomes with immune checkpoint inhibitors in melanoma
  • Impact, if any, of BRAF status on clinical decision-making

MODULE 4: Emerging Role of Immunotherapy in Gastrointestinal (GI) Cancers; Mutational and Neoantigen Burden as Predictors of Response — Dr Bendell

Faculty Presentation Topics

  • Role of neoantigens produced by somatic mutations as primary drivers in adaptive immune responses
  • Mutational or neoantigen burden as predictors of response and durability of clinical benefit to anti-PD-1/PD-L1 therapy; role of neoantigen intratumor heterogeneity in mediating response
  • Mismatch repair (MMR)-deficient versus proficient cancers and response to anti-PD-1/PD-L1 therapy; available assays to measure microsatellite instability (MSI)
  • Assessment of mutational load via next-generation sequencing

Faculty Case Presentation and Discussion

Relevant Clinical Issues

  • Integration of anti-PD-1/anti-PD-L1 checkpoint inhibitors into the treatment of metastatic colorectal cancer, gastric cancer and other GI cancers
  • Effect, if any, of MMR deficiency status on the clinical outcome of patients receiving anti-PD-1/anti-PD-L1 checkpoint inhibitors
  • Pathobiology of Lynch syndrome, indications for MSI testing and the efficacy of checkpoint inhibitors in patients with Lynch syndrome versus somatic presentation of MSI

MODULE 5: Checkpoint Inhibition in Hodgkin and Non-Hodgkin Lymphoma; Other Potential Biomarkers Predictive of Response — Dr Moskowitz

Faculty Presentation Topics

  • Immune gene signatures, especially those induced by interferon-γ
  • Identifying unique genetic alterations in classical Hodgkin lymphoma (cHL) as potential predictors of response to anti-PD-1/PD-L1 antibodies (eg, chromosome 9p24.1)
  • Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway involvement in PD-L1 expression
  • Strategies combining 2 or more methods for capturing the immune status of the tumor microenvironment (eg, PD-L1, TILs, genetic alterations) to identify predictive biomarker signatures

Faculty Case Presentation and Discussion

Relevant Clinical Issues

  • Integration of anti-PD-1/anti-PD-L1 checkpoint inhibitors into the treatment of cHL and sequencing with chemotherapy and/or targeted agents
  • Depth and duration of response to anti-PD-1/anti-PD-L1 checkpoint inhibitors in cHL
  • Epstein-Barr virus infection or genetic abnormalities in prediction of response to anti-PD-1/anti-PD-L1 monoclonal antibody therapy
  • Enhanced graft-versus-tumor effect after checkpoint blockade therapy in patients with cHL undergoing allogeneic stem cell transplant
  • Available data with immune checkpoint inhibitors in patients with various subtypes of non-Hodgkin lymphoma

Target Audience:
This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists, oncology nurses and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Appraise the rationale for and clinical data with approved anti-PD-1 and anti-PD-L1 antibodies in patients with various solid tumors and hematologic cancers.
  • Describe ongoing research to assist in the identification of biomarkers, tumor characteristics or other clinical features that are indicative of response to immune checkpoint inhibitors in patients with different types of cancer.
  • Compare and contrast expert perspectives on the indications for PD-L1 analysis in patients with metastatic non-small cell lung cancer (NSCLC), melanoma and other cancers, and, when appropriate, select individuals for PD-L1 assessment.
  • Appreciate the similarities and differences among various diagnostic assays available to determine PD-L1 status, and use this information to select a validated testing platform for use in practice.
  • Describe ongoing research to document the correlation between DNA mismatch repair deficiency in colorectal and noncolorectal gastrointestinal and other cancers and response to anti-PD-1 immune checkpoint inhibitors, and develop strategies to assess for this biomarker.
  • Recognize current investigational efforts to identify other potential biomarkers of response to checkpoint inhibition (tumor mutational burden, tumor-infiltrating lymphocytes, et cetera), and consider how they may be applied in future clinical practice.
  • Recall the design of ongoing clinical trials evaluating novel immunotherapeutic approaches, and counsel appropriately selected patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This live activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company and Incyte Corporation.

Grand Hyatt Washington
1000 H St NW
Washington, DC 20001
Hotel Phone: (202) 582-1234

6:30 PM – 7:00 PM (Eastern Time) — Registration and Buffet Dinner
7:00 PM – 9:00 PM (Eastern Time) — Educational Meeting

Meeting Room:
Independence Ballroom A (Level 5B)

 

The Grand Hyatt Washington hotel is conveniently located within walking distance (0.5 miles) of the Walter E Washington Convention Center.

This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists, oncology nurses and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

At this time preregistration for this CME activity is limited to clinicians in practice and healthcare providers involved in patient care or ongoing clinical/scientific research (excluding *industry or other professionals). Those individuals that meet this criteria, please continue below to register for this event. There is no registration fee for this event. Preregistration is advised as seating is limited.

For all other professionals*, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by clicking the second registration option below. Should seats become available for the program, we will notify you.

Registration for clinicians in practice / healthcare providers

I am a practicing physician, fellow, nurse or healthcare provider involved in the treatment of cancer or cancer research.

Registration for clinicians in practice/healthcare providers »
 
Registration for industry professionals*

Please note, a limited number of seats are available to industry professionals on a first come, first served basis.

STANDBY registration for industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in with our on-site registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.